High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis:: results from a 10-year longitudinal study

被引:227
作者
Syversen, S. W. [1 ,5 ]
Gaarder, P. I. [2 ]
Goll, G. L. [1 ]
Odegard, S. [1 ]
Haavardsholm, E. A. [1 ]
Mowinckel, P. [1 ]
van der Heijde, D. [3 ]
Landewe, R. [4 ]
Kvien, T. K. [1 ,5 ]
机构
[1] Diakonhjemmet Hosp, Dept Rheumatol, N-0319 Oslo, Norway
[2] Univ Hosp Ulleval, Dept Immunol & Transfus Med, Oslo, Norway
[3] Leiden Univ, Med Ctr, Dept Rheumatol, Leiden, Netherlands
[4] Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands
[5] Univ Oslo, Fac Med, Oslo, Norway
关键词
D O I
10.1136/ard.2006.068247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: New effective therapies with particularly good effect on joint destruction have highlighted the need for reliable predictors of radiographic progression in rheumatoid arthritis ( RA). Our objective was to assess the combined predictive role of a set of laboratory markers with regard to 10-year radiographic progression, and to examine the effect of anti-cyclic citrullinated peptide ( anti-CCP) level. Methods: A cohort of 238 patients with RA was followed longitudinally for 10 years with the collection of clinical data and serum samples. 125 patients with radiographs of the hands available at both baseline and after 10 years were included in this study. Radiographs were scored according to the van der Heijde modified Sharp score. Baseline sera were analysed for C-reactive protein, erythrocyte sedimentation rate (ESR), anti-CCP, IgA rheumatoid factor (RF) and IgM RF. Logistic regression analyses were used to identify predictors of radiographic progression and to examine the effect of anti-CCP level. Results: Anti-CCP ( OR 4.0; 95% CI 1.6 to 10.0) was the strongest independent predictor of radiographic progression. Female gender ( OR 3.3; 95% CI 1.3 to 7.6), high ESR ( OR 3.2; 95% CI 1.2 to 7.6) and a positive IgM RF ( OR 3.1; 95% CI 1.2 to 7.9) were also independent predictors. Compared with the anti-CCP-negative patients, patients with low to moderate levels of anti-CCP ( OR 2.6; 95% CI 0.9 to 7.2) and patients with high levels of anti-CCP ( OR 9.9; 95% CI 2.7 to 36.7) were more likely to develop radiographic progression. Conclusions: Anti-CCP, IgM RF, ESR and female gender were independent predictors of radiographic progression and could be combined into an algorithm for better prediction. Patients with high levels of anti-CCP were especially prone to radiographic progression, indicating that the anti-CCP level may add prognostic information.
引用
收藏
页码:212 / 217
页数:6
相关论文
共 33 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]   Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset [J].
Berglin, E ;
Johansson, T ;
Sundin, U ;
Jidell, E ;
Wadell, G ;
Hallmans, G ;
Rantapää-Dahlqvist, S .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (04) :453-458
[3]   The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[4]   Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference [J].
Bruynesteyn, K ;
van der Heijde, D ;
Boers, M ;
Saudan, A ;
Peloso, P ;
Paulus, H ;
Houben, H ;
Griffiths, B ;
Edmonds, J ;
Bresnihan, B ;
Boonen, A ;
van der Linden, S .
ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :913-920
[5]   Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[6]   EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) [J].
Combe, B. ;
Landewe, R. ;
Lukas, C. ;
Bolosiu, H. D. ;
Breedveld, F. ;
Dougados, M. ;
Emery, P. ;
Ferraccioli, G. ;
Hazes, J. M. W. ;
Klareskog, L. ;
Machold, K. ;
Martin-Mola, E. ;
Nielsen, H. ;
Silman, A. ;
Smolen, J. ;
Yazici, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :34-45
[7]   Prediction of radiological outcome in early rheumatoid arthritis in clinical practice:: role of antibodies to citrullinated peptides (anti-CCP) [J].
Forslind, K ;
Ahlmén, M ;
Eberhardt, K ;
Hafström, I ;
Svensson, B .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1090-1095
[8]   Sex:: a major predictor of remission in early rheumatoid arthritis? [J].
Forslind, K. ;
Hafstrom, I. ;
Ahlmen, M. ;
Svensson, B. .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (01) :46-52
[9]  
Houssien DA, 1998, SCAND J RHEUMATOL, V27, P46
[10]   ENZYME-LINKED-IMMUNOSORBENT-ASSAY (ELISA) SCREENING-TEST FOR DETECTION OF RHEUMATOID-FACTOR [J].
JONSSON, T ;
ARNASON, JA ;
VALDIMARSSON, H .
RHEUMATOLOGY INTERNATIONAL, 1986, 6 (05) :199-204